Invivyd, Inc. (IVVD) stock
IVVDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/3048% below fair value
$0.51−0.03 (-4.67%)
Close on Nov 17, 2026Market cap $151.09MP/E –Yield –
Invivyd cash
Cash and short-term investments held at the end of each period.
Invivyd's cash was $160.08M at Jun 30, 2026. For fiscal 2025 it was $226.69M, up 226.9% from the year before. The highest annual figure on record is $542.22M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $226.69M | +226.9% |
| FY2024 | Dec 31, 2024 | $69.35M | -65.4% |
| FY2023 | Dec 31, 2023 | $200.64M | +117.9% |
| FY2022 | Dec 31, 2022 | $92.08M | -83.0% |
| FY2021 | Dec 31, 2021 | $542.22M | +371.5% |
| FY2020 | Dec 31, 2020 | $114.99M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $160.08M | +358.6% |
| Q1 FY2026 | Mar 31, 2026 | $184.15M | +283.0% |
| Q4 FY2025 | Dec 31, 2025 | $226.69M | +226.9% |
| Q3 FY2025 | Sep 30, 2025 | $84.97M | -20.5% |
| Q2 FY2025 | Jun 30, 2025 | $34.91M | -76.4% |
| Q1 FY2025 | Mar 31, 2025 | $48.08M | -74.6% |
| Q4 FY2024 | Dec 31, 2024 | $69.35M | -65.4% |
| Q3 FY2024 | Sep 30, 2024 | $106.87M | -41.2% |
| Q2 FY2024 | Jun 30, 2024 | $147.88M | +21.3% |
| Q1 FY2024 | Mar 31, 2024 | $189.39M | +49.7% |
| Q4 FY2023 | Dec 31, 2023 | $200.64M | +117.9% |
| Q3 FY2023 | Sep 30, 2023 | $181.82M | -34.6% |
| Q2 FY2023 | Jun 30, 2023 | $121.95M | -74.3% |
| Q1 FY2023 | Mar 31, 2023 | $126.47M | -76.2% |
| Q4 FY2022 | Dec 31, 2022 | $92.08M | -83.0% |
| Q3 FY2022 | Sep 30, 2022 | $278.15M | -41.8% |
| Q2 FY2022 | Jun 30, 2022 | $474.89M | +21.0% |
| Q1 FY2022 | Mar 31, 2022 | $532.22M | +483.3% |
| Q4 FY2021 | Dec 31, 2021 | $542.22M | +371.5% |
| Q3 FY2021 | Sep 30, 2021 | $478.27M | +884.6% |
| Q2 FY2021 | Jun 30, 2021 | $392.51M | – |
| Q1 FY2021 | Mar 31, 2021 | $91.25M | – |
| Q4 FY2020 | Dec 31, 2020 | $114.99M | – |
| Q3 FY2020 | Sep 30, 2020 | $48.58M | – |
See a number that looks wrong?